<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046041</url>
  </required_header>
  <id_info>
    <org_study_id>1051</org_study_id>
    <nct_id>NCT05046041</nct_id>
  </id_info>
  <brief_title>Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal</brief_title>
  <official_title>A Study of Acceptability and Feasibility of an Outpatient &quot;Day Procedure&quot; for Medical Abortion at 13-18 Weeks Gestation in Two Public Sector Hospitals in Nepal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KIST Medical College and Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Research on Environment Health and Population Activities (CREHPA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bharatpur Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lumbini Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the safety, acceptability and feasibility of an outpatient &quot;day&#xD;
      procedure&quot; for medical abortion at 13-18 weeks gestation in two public sector facilities. It&#xD;
      also seeks to document the roles of health workers in providing services related to later&#xD;
      abortion care and to document the costs of this day procedure to the health system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with method success on the same day as misoprostol initiation.</measure>
    <time_frame>0 - 48 hours after first dose of mifepristone</time_frame>
    <description>Success is defined as expelling fetus and placenta without surgical intervention and return home on the same day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average induction-to-abortion interval</measure>
    <time_frame>0 - 48 hours after first misoprostol dose</time_frame>
    <description>Time interval from administration of the first misoprostol dose until expulsion of both fetus and placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of total doses of misoprostol</measure>
    <time_frame>0 - 48 hours after first misoprostol dose</time_frame>
    <description>Total misoprostol doses administered from induction to delivery of placenta.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>0-2 weeks after initial visit</time_frame>
    <description>Adverse events include extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, or prolonged hospitalization, any complications (immediate and delayed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of tasks performed by different cadres of study staff</measure>
    <time_frame>0 - 72 hours after receipt of mifepristone</time_frame>
    <description>Tasks evaluated include counseling, monitoring vital signs, administering drugs, monitoring woman's condition, post-abortion contraception, managing discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average total hospital admission time</measure>
    <time_frame>Within 0 - 48 hours after the second dose of misoprostol</time_frame>
    <description>Total hospital admission time, including: 1) total admission time during treatment with misoprostol and abortion recovery 2) Additional hospital time required for the evaluation and management of complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain scores</measure>
    <time_frame>0 - 48 hours after first dose of misoprostol</time_frame>
    <description>Severity incidence based on a 0-10 point pain scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of individual side effects experienced by participants</measure>
    <time_frame>0 - 48 hours after first dose of misoprostol</time_frame>
    <description>Side effects evaluated include diarrhea, nausea, vomiting, fever, chills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of reported complications</measure>
    <time_frame>0-2 weeks after initial visit</time_frame>
    <description>Participants who returned to a health facility for evaluation and management of complications within 2 weeks of taking mifepristone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of satisfied participants</measure>
    <time_frame>2 weeks after initial visit</time_frame>
    <description>Participants who report high satisfaction with service</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Abortion in Second Trimester</condition>
  <arm_group>
    <arm_group_label>Mifepristone + Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone + Misoprostol</intervention_name>
    <description>A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.</description>
    <arm_group_label>Mifepristone + Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have an ongoing pregnancy of 13-18 weeks gestation&#xD;
&#xD;
          2. Meet legal criteria to obtain abortion at 13-18 weeks gestation (Legal criteria&#xD;
             include pregnancy resulting from rape or incest, fetal malformation and/or if the&#xD;
             pregnancy affects the physical or mental health of the woman)&#xD;
&#xD;
          3. Have access to a phone where she can be reached at the 2-week follow up or willing to&#xD;
             return to the clinic for an in-person interview with the research assistant&#xD;
&#xD;
          4. Be willing to follow study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications&#xD;
             to the use of mifepristone or misoprostol&#xD;
&#xD;
          2. Any contraindications to vaginal delivery&#xD;
&#xD;
          3. More than one prior cesarean delivery&#xD;
&#xD;
          4. Living more than 2 hours away from the hospital&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga Platais</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly Winikoff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anand Tamang</last_name>
    <role>Principal Investigator</role>
    <affiliation>CREHPA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sajan K.C, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bharatpur Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shreedhar Acharya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lumbini Provincial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bharatpur Hospital</name>
      <address>
        <city>Bharatpur</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumbini Provincial Hospital</name>
      <address>
        <city>ButwƒÅl</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

